Clinical Trial Detail

NCT ID NCT04468061
Title Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Sacituzumab govitecan-hziy

Pembrolizumab + Sacituzumab govitecan-hziy

Age Groups: adult senior

No variant requirements are available.